http://www.medesispharma.com Medesis Pharma Wed, 18 Aug 2010 07:14:03 +0000 http://backend.userland.com/rss092 en http://www.medesispharma.com/events/ehdn-2010 The objective of this randomised, double blind, placebo controlled study was to evaluate the tolerability of NP01 in healthy male volunteers following single and repeat administration of 180ug of the drug’s active ingredient, vanadium. The company reported that there were no serious adverse events and that the drug was well ... http://www.medesispharma.com/press/medesis-pharma-successfully-completes-phase-i-clinical-trial-of-np01 More details concerning this meeting can be found here http://www.medesispharma.com/events/epic-biotech More details of the meeting can be found here http://www.medesispharma.com/news/smi-5th-conference-on-rnai-sirna-and-mirna On Wednesday 24th March, Medesis will present the latest developments in the use of Aonys® for systemic delivery of oligonucleotides in a talk entitled "Pharmaceutical Development of a Novel Oligonucleotide Delivery Formulation" More information on the 3rd DIA Oligonucleotide-based Therapeutics Conference: “Where Regulators and Industry Partner to Advance Oligonucleotide ... http://www.medesispharma.com/events/dia-3rd-oligonucleotide-based-therapeutics-conference Medesis Pharma will participate in the 2èmes rencontres Euro-Régionales de la biotechnologie et de la santé.  More information can be found here http://www.medesispharma.com/events/2emes-rencontres-euro-regionales-de-la-biotechnologie-et-de-la-sante On 5th November 2009, Medesis Pharma received a positive opinion from the Committee for Orphan Medicinal Products (COMP) for an orphan drug designation for the following product: Lithium citrate tetrahydrate (in reverse-micelle formulation) for the treatment of Huntington’s disease...... http://www.medesispharma.com/press/letter-to-patients-suffering-from-huntingtons-disease Medesis Pharma's treatment for Huntington's disease has received a positive opinion for orphan drug designation from the Committee for Ophan Medicinal Products (COMP).    Lithium citrate tetrahydrate (in reverse-micelle formulation) for treatment of Huntington's disease (NP03)  fulfilled the requirements for orphan drug designation based upon the level of prevalence of ... http://www.medesispharma.com/news/medesis-pharmas-treatment-for-huntingtons-disease-has-received-a-positive-opinion-for-orphan-drug-designation-from-the-committee-for-ophan-medicinal-products-comp For more information on this meeting please click here http://www.medesispharma.com/events/xxiviemes-journees-scientifiques-du-gtrvxxiviemes-journees-scientifiques-du-gtrv For more information on this meeting click here http://www.medesispharma.com/events/eurobiomed-colloque-maladies-rares-et-ophelineseurobiomed-colloque-maladies-rares-et-ophelines